Journals / Molecular Imaging and Radionuclide Therapy / 2011 / Cilt: 20 - Sayı: 1

L-Karnitin’in siçanlarda sisplatin nefrotoksisitesine karşı koruyuculuğu: kantitatif böbrek Tc 99m DMSA Uptake’ini kullanarak amifostinle karşılaştırma

L-Carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake

Pages
1–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results showed that L-carnitine significantly attenuates the cisplatin-induced nephrotoxicity as amifostin. (MIRT 2011; 20: 1-6)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to investigate the cytoprotective effect of L-carnitine against cisplatin-induced nephrotoxicity and to compare its efficacy with that of amifostin by quantitative renal Tc 99m DMSA uptake.
📊
Key Findings & Data:Material and Methods: Male Wistar rats were randomly divided into six groups of six animals each. 1) Control (saline; 5 ml/kg intraperitoneally); 2) L-carnitine (CAR; 300 mg/kg intraperitoneally); 3) Amifostine (AMI; 200 mg /kg intraperitoneally); 4) Cisplatin (CIS;7 mg/kg intraperitoneally); 5) Cisplatin plus L-carnitine (CIS + CAR); 6) Cisplatin plus amifostine (CIS + AMI).
💡
Conclusion & Impact:Conclusion: The results showed that L-carnitine significantly attenuates the cisplatin-induced nephrotoxicity as amifostin. (MIRT 2011; 20: 1-6)
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to investigate the cytoprotective effect of L-carnitine against cisplatin-induced nephrotoxicity and to compare its efficacy with that of amifostin by quantitative renal Tc 99m DMSA uptake. Material and Methods: Male Wistar rats were randomly divided into six groups of six animals each. 1) Control (saline; 5 ml/kg intraperitoneally); 2) L-carnitine (CAR; 300 mg/kg intraperitoneally); 3) Amifostine (AMI; 200 mg /kg intraperitoneally); 4) Cisplatin (CIS;7 mg/kg intraperitoneally); 5) Cisplatin plus L-carnitine (CIS + CAR); 6) Cisplatin plus amifostine (CIS + AMI). L-carnitine and amifostine were injected 30 minutes before cisplatin in Group 5 and 6. Tc 99m DMSA, 7.4 MBq/0.2 ml, was injected through the tail vein 72 hours after the drug administration. Rats were killed and kidneys removed by dissection 2 hours after the injection of the radiopharmaceutical. The percentage of the injected dose per gram of kidney tissue (%ID/g) was calculated. Renal function was monitored by measuring BUN and plasma levels of creatinine. Lipid peroxidation and glutathione content were determined by measuring malondialdehyde (MDA) and reduced glutathione (GSH) in kidney tissue homogenates. Results: Tc 99m DMSA uptake per gram tissue of the kidney as %ID/g was 29.54±4.72, 29.86 ± 7.47 and 26.37 ± 4.54 in the control, CAR and AMI groups respectively. %ID/g was the lowest of all the groups, 11.60±3.59 (p<0.01), in the cisplatin group. Carnitine or amifostine administration 30 minutes before cisplatin injection resulted a significant increase in %ID/g, 21.28±7.73 and 18.97±3.24 respectively, compared to those of cisplatin-treated rats (p<0.002). A marked increase in plasma BUN and creatinine indicating nephrotoxicity and acute renal failure was observed in the cisplatin-treated group. MDA and GSH levels were concordant with cisplatin-induced oxidative stress in the kidney tissue. Conclusion: The results showed that L-carnitine significantly attenuates the cisplatin-induced nephrotoxicity as amifostin. (MIRT 2011; 20: 1-6)

Özet

Amaç: Bu çalışmanın amacı sisplatinin neden olduğu nefrotoksisiteye karşı L-karnitinin koruyucu etkisini ve bu etkiyi kantitatif renal Tc 99m DMSA uptake’ini kullanarak amifostinin etkisiyle karşılaştırmaktı. Gereç ve Yöntemler: Erkek Wistar sıçanlar her biri 6 hayvandan oluşan 6 gruba ayrıldı: 1) Kontrol grubu (serum fizyolojik, 5 ml/kg); 2) L-karnitin (CAR; 300 mg/kg intraperitoneal); 3)Amifostin (AMI; 200 mg /kg intraperitoneal); 4) Sisplatin (CIS; 7 mg/kg intraperitoneal); 5) Sisplatin artı L-karnitin (CIS + CAR); 6) Sisplatin artı amifostin (CIS + AMI). Grup 5 ve 6’da L-karnitin ve amifostin sisplatinden 30 dakika once enjekte edildi. İlaçlar verildikten sonraki 72. saatte kuyruk veninden 7.4 MBq/0.2 ml Tc 99m DMSA enjekte edildi.. Radyofarmasötiğin enjeksiyonundan 120 dakika sonra sıçanlar öldürüldü ve böbrekleri çıkarıldı. Enjekte edilen dozun her bir böbrek dokusu gramındaki oranı (%ID/g) hesaplandı. Böbrek fonksiyonu BUN ve plazma kreatinin düzeyi ölçümü ile değerlendirildi. Böbrek dokusu homojenatlarında malondialdehit (MDA) ve glutatyon (GSH) ölçümü ile lipid peroksidasyonu ve glutatyon seviyesi belirlendi. Bulgular: Kontrol, CAR ve AMI gruplarında %ID/g olarak Tc 99m DMSA uptake’i sırasıyla 29.54±4.72, 29.86±7.47 and 26.37 4.54 olarak hesaplandı. Sisplatin grubunda tüm gruplar içinde en düşük %ID/g, (11.60±3.59) (p<0.01), değeri gözlendi. Sisplatin uygulamasından 30 dakika önce L-karnitin veya amifostin verilmesi sadece sisplatin verilen grupla kıyaslandığında %ID/g’de anlamlı artışa (sırasıyla, 21.28±7.73 ve 18.97±3.24) neden oldu (p<0.002). Sisplatin verilen grupta plazma BUN ve kreatinin düzeylerinde nefrotoksisite ve akut renal yetmezliği gösteren belirgin artışlar gözlendi. MDA ve GSH düzeyleri sisplatinin böbrek dokusunda neden olduğu oksidatif stres ile uyumlu idi. Sonuç: Bulgular L-karnitinin amifostine benzer şekilde sisplatinin neden olduğu nefrotoksisiteyi anlamlı düzeyde azalttığını göstermektedir. (MIRT 2011; 20: 1-6)

🔖

Cite This Article

YÜREKLİ, Y., ÜNAK, P., YENİSEY, Ç., ERTAY, T., BİBER, F. Z. M., MEDİNE, E. İ. (2011). L-Karnitin’in siçanlarda sisplatin nefrotoksisitesine karşı koruyuculuğu: kantitatif böbrek Tc 99m DMSA Uptake’ini kullanarak amifostinle karşılaştırma. Molecular Imaging and Radionuclide Therapy, Cilt: 20 - Sayı: 1, 1–6. https://ajindex.com/articles/295276

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001;67:93-130
  2. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115-124
  3. Pabla N, Dong Z. Cisplatin nephrotoxicity:mechanisms and renoprotective strategies.Kidney Int 2008;73:994-1007
  4. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001;24:19-38
  5. Chapela SP, Kriguer N, Fernández E.H, Stella CA. Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport. Mini- Reviews in Medicinal Chemistry 2009; 9:1518-1526 6. Martelli E, Caso V. Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp Clin Res 2001;27:27-49
  6. Di Cesare Mannelli L, Ghelardini C, Calvani M, Nicolai R, Mosconi L, Vivoli E, Pacini A, Bartolini A. Protective effect of acetyl- L –carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci 2007;26:820-827
  7. Di Cesare Mannelli L, Ghelardini C, Calvani M, Nicolai R, Mosconi L, Toscano A, Pacini A, Bartolini A. Neuroprotective effects of acetyl- L -carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J Neurosci Res 2009;87:200-207
  8. Zhu X, Sato EF, Wang Y, Nakamura H, Yodoi J, Inoue M. Acetyl- L -carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch Biochem Biophys 2008;478:154-160
  9. Mahaney Jr FX. Agent designed for war now in doctor’s armamentarium. J Natl Cancer Inst 1990;82:255-257
  10. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002;13:181-209
  11. Culy CR, Spencer CM. Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001;61:641-684
  12. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-145
  13. Muller-Suur R, Gutsche HU. Tubular reabsorption of technetium-99m DMSA. J Nucl Med 1995; 36:1654-1658. 15. van Luyk, WH, GJ Ensing, DA Piers. Low renal uptake of Tc 99m DMSA in patients with proximal tubular dysfunction. Eur J Nucl Med 1983; 8:404-405
  14. Provoo